This is the company's first solution to treat Early Onset Scoliosis patients, specifically those associated with or at risk of Thoracic Insufficiency Syndrome.
Bone Biologics is focusing development of a bone graft substitute for bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications.